Claims for Patent: 7,053,092

Summary for Patent: 7,053,092

Title:	5-HT1a receptor subtype agonist
Abstract:	The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s):	Jordon; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	10/055,915
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,053,092
Patent Claims:	1. A method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype wherein the disorder is depression selected from the group consisting of endogenous depression, major depression, melancholia and treatment resistant depression, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal: ##STR00003## wherein the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton is a single or a double bond. 2. The method of claim 1 wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyri- l.